Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax™

Rhea-AI Summary

Biomind Labs Inc. (OTC: BMNDF) has achieved a significant milestone by optimizing a new extraction method that enhances the purity and yield of N,N-dimethyltryptamine (DMT) for their New Chemical Entity (NCE), Triptax™. This method has received FDA Investigational New Drug clearance, supporting future clinical trials for treating neurological disorders such as depression. The scalable and environmentally friendly production aligns with the company’s goals of affordable pharmaceuticals. CEO Alejandro Antalich emphasized the cost benefits and compliance with Good Manufacturing Practices, marking progress in their pharmaceutical development.

Positive

• Successfully optimized extraction method for DMT, increasing purity and yield.
• FDA Investigational New Drug clearance for Triptax™ allows advancement of clinical trials.
• Scalable, affordable, and environmentally friendly production aligns with company goals.

Negative

• No significant negative aspects noted.

TORONTO--(BUSINESS WIRE)-- Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has successfully completed the optimization of a new extraction method to increase the purity and yield of N,N-dimethyltryptamine (“DMT”). DMT was submitted as a Company’s New Chemical Entity (“NCE”) Triptax™. The U.S. Food and Drug Administration (the “FDA”) has given the Company Investigational New Drug clearance related to Triptax™.

“This achievement marks a new major step in our objective to upgrade the development and production of our own Active Pharmaceutical Ingredients. This method can be scalable to potentially reach an affordable and environmentally friendly production of the NCE Triptax™ under Good Manufacturing Practices compliance, as is required by the pharmaceutical industry. Through this optimized process, the DMT crystals obtained could be used as an API or as a chemical precursor of the Company’s novel formulations to potentially treat a wide range of neurological disorders such as depression, treatment resistant depression and major depressive disorder. The reduction of production costs by this method while increasing the levels of purity and yield, aligns with one of the Company’s core principal of developing of affordable and accessible new pharmaceuticals,” said Alejandro Antalich, CEO of Biomind Labs.

“With this method, our procedures align to FDA requirements, which is imperative in advancing commercial clinical trials aimed at registering novel pharmaceuticals. Several features have been explored and analyzed, from a variety of organic solvents, incubation periods, to stirring and temperature conditions, among others, to finally improve the production of DMT in terms of purity and yield, which results in lower production costs,” said Paola Díaz Dellavalle, CSO of Biomind Labs.

About Biomind Labs Inc.
Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this document include, among others, statements relating to the Company’s ability to scientifically harness the medicinal power of psychedelic molecules to treat patients suffering from neurological and psychiatric disorders, the Company’s ability to develop and produce its own API; the Company’s ability to scale and potentially reach an affordable and environmentally friendly production of the NCE Triptax™ under Good Manufacturing Practices; the Company’s ability to create novel formulations and their potential treatment results; the Company’s ability to advance commercial clinical trials aimed at registering novel pharmaceuticals; the Company’s ability to provide patients access to affordable and modern-day treatments; and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The FDA, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in commercial clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005225/en/

For more information, please contact:

Biomind Labs Inc.

Alejandro Antalich

Chief Executive Officer

Email: info@biomindlabs.com

Tel: + 598 97 702500

Source: Biomind Labs Inc.

FAQ

What recent achievement did Biomind Labs (BMNDF) announce?

Biomind Labs announced the successful optimization of an extraction method for DMT, enhancing its purity and yield.

What is Triptax™ in relation to Biomind Labs?

Triptax™ is the New Chemical Entity developed by Biomind Labs that includes DMT, recently given FDA Investigational New Drug clearance.

How does the new extraction method benefit Biomind Labs?

The new extraction method increases the purity and yield of DMT, potentially reducing production costs and supporting scalable manufacturing.

What conditions does Triptax™ aim to treat?

Triptax™ aims to treat neurological disorders, including depression and treatment-resistant depression.